The value of high adherence to tamoxifen in women with breast cancer: A community-based cohort study

British Journal of Cancer

Volumn 109, Issue 5, 2013, Pages 1172-1180

  McCowan, C ^a   Wang, S ^b   Thompson, A M ^c   Makubate, B ^d   Petrie, D J ^e  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d BOTSWANA INTERNATIONAL UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Botswana)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

tamoxifen; breast cancer; adherence; cost effectiveness; QALYs

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURVIVAL; FEMALE; HEALTH CARE COST; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL AUDIT; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SURVIVAL TIME; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; REGISTRIES; TAMOXIFEN;

EID: 84883740983     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.464     Document Type: Article

References (39)

1. Appleby J, Devlin N, Parkin D (2007) NICE's cost effectiveness threshold. BMJ 335(7616): 358-359. (Pubitemid 47359304)
2. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen. Cancer 109(5): 832-839.
3. Burnham KP, Anderson DR (2004) Multimodel Inference: Understanding AIC and BIC in Model Selection. Sociol Methods Res 33(2): 261-304. (Pubitemid 39519124)
4. Delea T, Karnon J, Sofrygin O, Thomas S, Papo N, Barghout V (2007) Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer 7(8): 608-618. (Pubitemid 47025818)
5. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6): 613-619.
6. Dezentje VO, van Blijderveen NJC, Gelderblom H, Putter H, van Herk-SukelMPP, Casparie MK, Egberts ACG, Nortier JWR, Guchelaar H-J (2010) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28(14): 2423-2429.
7. Early Breast Cancer Trialists' Collaborative Group (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793): 771-784.
8. Glasziou P, Haas M (1994) An Economic Evaluation of the Use of Tamoxifen in the Treatment of Early Breast Cancer. CHERE, University of Technology: Sydney.
9. Greving J, Visseren F, Gd WIT, Algra A (2011) Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ 342: d1672.
10. Hadji P, Ziller V, Kyvernitakis J, Bauer M, Haas G, Schmidt N, Kostev K (2013) Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat 138(1): 185-191.
11. Hershman D, Shao T, Kushi L, Buono D, Tsai W, Fehrenbacher L, Kwan M, Gomez S, Neugut A (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2): 529-537.
12. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y, Fehrenbacher L, Lin Gomez S, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Oncol 28(27): 4120-4128.
13. Huiart L, Ferdynus C, Giorgi R (2013) A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat 138(1): 325-328.
14. Indurkhya A, Mitra N, Schrag D (2006) Using propensity scores to estimate the cost-effectiveness of medical therapies. Stat Med 25(9): 1561-1576.
15. ISD Scotland, Scottish Government (2012a) Costs: Finance (online). Available at http://www.isdscotland.org/Health-Topics/Finance/Costs/(accessed 29 January 2013).
16. ISD Scotland, Scottish Government (2012b) Community dispensing: Prescription Cost Analysis (online) Available at www.isdscotland.org/Health- Topics/Prescribing-and-Medicines/Community-Dispensing/Prescription-Cost- Analysis/(accessed 29 January 2013).
17. Lidgren M, Wilking N, Jönsson B, Rehnberg C (2007) Health related quality of life in different states of breast cancer. Qual Life Res 16(6): 1073-1081. (Pubitemid 47174889)
18. Ma AMT, Barone J, Wallis AE, Wu NJ, Garcia LB, Estabrook A, Rosenbaum-Smith SM, Tartter PI (2008) Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg 196(4): 500-504.
19. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7): 1515-1524.
20. McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11): 1763-1768.
21. McDonald HP, Garg AX, Haynes RB (2002) Interventions to enhance patient adherence to medication prescriptions JAMA 288(22): 2868-2879. (Pubitemid 35425073)
22. Murphy C, Bartholomew LK, Carpentier M, Bluethmann S, Vernon S (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2): 459-478.
23. Murthy V, Bharia G, Sarin R, Murthy V, Bharia G, Sarin R (2002) Tamoxifen non-compliance: does it matter? Lancet Oncol 3(11): 654. (Pubitemid 35314907)
24. Narod SA (2010) Compliance With Tamoxifen in Women With Breast Cancer and a BRCA1 or BRCA2 Mutation. J Clin Oncol 28(33): e698-e699.
25. National Institute for Health and Clinical Excellence (2011) Discounting of health benefits in special circumstances (online). Available at http://www. nice.org.uk/media/955/4F/Clarification-to-section-5.6-of-the-Guide-to-Methods- of-Technology-Appraisals.pdf (accessed 29 January 2013).
26. Osterberg L, Blaschke T (2005) Adherence to Medication. N Engl J Med 353(5): 487-497. (Pubitemid 41127293)
27. Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, Yood MU, Wei F, Silliman RA, Owusu C, Buist DSM, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, Yood MU, Wei F, Silliman RA (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26(4): 549-555. (Pubitemid 351264347)
28. Palisade. @Risk 5.7 (2009) Ithaca NY: Palisade Corporation.
29. Patridge A, Wang P, Winer E, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4): 602-606. (Pubitemid 46621892)
30. Royston P (2004) Multiple imputation of missing values. Stata J 4: 227-241.
31. Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59(1): 56-66.
32. Sabaté E. World Health Organization (2003) Adherence to long-term therapies: evidence for action (online). Available at http://www.who.int/chp/ knowledge/publications/adherence-report/en/(accessed 29 January 2013).
33. Scottish Government (2012) Scottish index of multiple deprivation (online). Available at http://www.scotland.gov.uk/Topics/Statistics/SIMD (accessed 29 January 2013).
34. Scottish Intercollegiate Guideline Network Guidelines (2005) Breast Cancer in Women: A National Clinical Guideline. Scottish Intercollegiate Guideline Network: Edinburgh.
35. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA (2004) New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 57(12): 1288-1294. (Pubitemid 40023149)
36. Van Buuren S, Boshuizen HC, Knook DL (1999) Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 18(6): 681-694. (Pubitemid 29126744)
37. van Herk-Sukel M, van de Poll-Franse L, Voogd A, Nieuwenhuijzen G, Coebergh J, Herings R (2010) Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 122(3): 843-851.
38. Yang JJ, Park SK, Cho LY, Han W, Park B, Kim H, Lee KS, Hahn SK, Cho SI, Ahn SH, Noh DY. Korean Breast Cancer S (2010) Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database. Clin Ther 32(6): 1122-1138.
39. Yood MU, Owusu C, Buist DS, Geiger AM, Field TS, Thwin SS, Lash TL, Prout MN, Wei F, Quinn VP, Frost FJ, Silliman RA, Yood MU, Owusu C, Buist DSM, Geiger AM, Field TS, Thwin SS, Lash TL, Prout MN, Wei F, Quinn VP, Frost FJ, Silliman RA (2008) Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg 206(1): 66-75. (Pubitemid 350267255)